메뉴 건너뛰기




Volumn 54, Issue 4, 2015, Pages 307-314

Mass spectrometric quantification of glucosylsphingosine in plasma and urine of type 1 Gaucher patients using an isotope standard

Author keywords

Gaucher disease; Glucocerebrosidase; Glucosylsphingosine; LC MS MS; Mass spectrometry; Quantification

Indexed keywords

13C5 LABELLED GLUCOSYLSPHINGOSINE; GLUCOSYLSPHINGOSINE; ISOTOPE; SPHINGOSINE; UNCLASSIFIED DRUG;

EID: 84964292886     PISSN: 10799796     EISSN: 10960961     Source Type: Journal    
DOI: 10.1016/j.bcmd.2015.01.006     Document Type: Article
Times cited : (55)

References (32)
  • 2
    • 0025869216 scopus 로고
    • Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher's disease
    • Barton N.W., Brady R.O., Dambrosia J.M., Di Bisceglie A.M., Doppelt S.H., Hill S.C., et al. Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher's disease. N. Engl. J. Med. 1991, 324:1464-1470.
    • (1991) N. Engl. J. Med. , vol.324 , pp. 1464-1470
    • Barton, N.W.1    Brady, R.O.2    Dambrosia, J.M.3    Di Bisceglie, A.M.4    Doppelt, S.H.5    Hill, S.C.6
  • 3
    • 77954693904 scopus 로고    scopus 로고
    • Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience
    • Zimran A., Altarescu G., Philips M., Attias D., Jmoudiak M., Deeb M., Wang N., Bhirangi K., Cohn G.M., Elstein D. Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience. Blood 2010, 115(23):4651-4656.
    • (2010) Blood , vol.115 , Issue.23 , pp. 4651-4656
    • Zimran, A.1    Altarescu, G.2    Philips, M.3    Attias, D.4    Jmoudiak, M.5    Deeb, M.6    Wang, N.7    Bhirangi, K.8    Cohn, G.M.9    Elstein, D.10
  • 5
    • 0034728914 scopus 로고    scopus 로고
    • Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis
    • Cox T., Lachmann R., Hollak C., Aerts J., van W.S., Hrebicek M., et al. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 2000, 355:1481-1485.
    • (2000) Lancet , vol.355 , pp. 1481-1485
    • Cox, T.1    Lachmann, R.2    Hollak, C.3    Aerts, J.4    van, W.S.5    Hrebicek, M.6
  • 6
    • 10744226382 scopus 로고    scopus 로고
    • The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement
    • Cox T.M., Aerts J.M., Andria G., Beck M., Belmatoug N., Bembi B., et al. The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. J. Inherit. Metab. Dis. 2003, 26:513-526.
    • (2003) J. Inherit. Metab. Dis. , vol.26 , pp. 513-526
    • Cox, T.M.1    Aerts, J.M.2    Andria, G.3    Beck, M.4    Belmatoug, N.5    Bembi, B.6
  • 9
    • 0028220472 scopus 로고
    • Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease
    • Hollak C.E., van W.S., van Oers M.H., Aerts J.M. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J. Clin. Invest. 1994, 93:1288-1292.
    • (1994) J. Clin. Invest. , vol.93 , pp. 1288-1292
    • Hollak, C.E.1    van, W.S.2    van Oers, M.H.3    Aerts, J.M.4
  • 10
    • 9144222696 scopus 로고    scopus 로고
    • Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention
    • Boot R.G., Verhoek M., de F.M., Hollak C.E., Maas M., Bleijlevens B., et al. Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood 2004, 103:33-39.
    • (2004) Blood , vol.103 , pp. 33-39
    • Boot, R.G.1    Verhoek, M.2    de, F.M.3    Hollak, C.E.4    Maas, M.5    Bleijlevens, B.6
  • 11
    • 84911998784 scopus 로고    scopus 로고
    • Value of plasma chitotriosidase to assess non-neuronopathic Gaucher disease severity and progression in the era of enzyme replacement therapy
    • van Dussen L., Hendriks E.J., Groener J.E., Boot R.G., Hollak C.E., Aerts J.M. Value of plasma chitotriosidase to assess non-neuronopathic Gaucher disease severity and progression in the era of enzyme replacement therapy. J. Inherit. Metab. Dis. 2014, 37(6):991-1001.
    • (2014) J. Inherit. Metab. Dis. , vol.37 , Issue.6 , pp. 991-1001
    • van Dussen, L.1    Hendriks, E.J.2    Groener, J.E.3    Boot, R.G.4    Hollak, C.E.5    Aerts, J.M.6
  • 13
    • 80054841258 scopus 로고    scopus 로고
    • Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response
    • Dekker N., van D.L., Hollak C.E., Overkleeft H., Scheij S., Ghauharali K., et al. Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response. Blood 2011, 118:e118-e127.
    • (2011) Blood , vol.118 , pp. e118-e127
    • Dekker, N.1    van, D.L.2    Hollak, C.E.3    Overkleeft, H.4    Scheij, S.5    Ghauharali, K.6
  • 15
    • 78650614891 scopus 로고    scopus 로고
    • Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage
    • Mistry P.K., Liu J., Yang M., Nottoli T., McGrath J., Jain D., et al. Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:19473-19478.
    • (2010) Proc. Natl. Acad. Sci. U. S. A. , vol.107 , pp. 19473-19478
    • Mistry, P.K.1    Liu, J.2    Yang, M.3    Nottoli, T.4    McGrath, J.5    Jain, D.6
  • 16
    • 84916227639 scopus 로고    scopus 로고
    • Inhibition of UDP-glucosylceramide synthase in mice prevents Gaucher disease-associated B-cell malignancy
    • Pavlova E.V., Archer J.Z., Wang S., Dekker N., Aerts J.M., Karlsson S., Cox T.M. Inhibition of UDP-glucosylceramide synthase in mice prevents Gaucher disease-associated B-cell malignancy. J. Pathol. 2015, 235(1):113-124.
    • (2015) J. Pathol. , vol.235 , Issue.1 , pp. 113-124
    • Pavlova, E.V.1    Archer, J.Z.2    Wang, S.3    Dekker, N.4    Aerts, J.M.5    Karlsson, S.6    Cox, T.M.7
  • 18
    • 84897550720 scopus 로고    scopus 로고
    • Multiplex tandem mass spectrometry analysis of novel plasmalyso-Gb[U+2083]-related analogues in Fabry disease
    • Boutin M., Auray-Blais C. Multiplex tandem mass spectrometry analysis of novel plasmalyso-Gb[U+2083]-related analogues in Fabry disease. Anal. Chem. 2014, 86(7):3476-3483.
    • (2014) Anal. Chem. , vol.86 , Issue.7 , pp. 3476-3483
    • Boutin, M.1    Auray-Blais, C.2
  • 20
    • 34147204029 scopus 로고    scopus 로고
    • HPLC for simultaneous quantification of total ceramide, glucosylceramide, and ceramide trihexoside concentrations in plasma
    • Groener J.E., Poorthuis B.J., Kuiper S., Helmond M.T., Hollak C.E., Aerts J.M. HPLC for simultaneous quantification of total ceramide, glucosylceramide, and ceramide trihexoside concentrations in plasma. Clin. Chem. 2007, 53:742-747.
    • (2007) Clin. Chem. , vol.53 , pp. 742-747
    • Groener, J.E.1    Poorthuis, B.J.2    Kuiper, S.3    Helmond, M.T.4    Hollak, C.E.5    Aerts, J.M.6
  • 21
    • 84874618709 scopus 로고    scopus 로고
    • Quantification of globotriaosylsphingosine in plasma and urine of fabry patients by stable isotope ultraperformance liquid chromatography-tandem mass spectrometry
    • Gold H., Mirzaian M., Dekker N., Joao F.M., Lugtenburg J., Codee J.D., et al. Quantification of globotriaosylsphingosine in plasma and urine of fabry patients by stable isotope ultraperformance liquid chromatography-tandem mass spectrometry. Clin. Chem. 2013, 59:547-556.
    • (2013) Clin. Chem. , vol.59 , pp. 547-556
    • Gold, H.1    Mirzaian, M.2    Dekker, N.3    Joao, F.M.4    Lugtenburg, J.5    Codee, J.D.6
  • 22
    • 33845261493 scopus 로고
    • A rapid method of total lipid extraction and purification
    • Bligh E.G., Dyer W.J. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 1959, 37:911-917.
    • (1959) Can. J. Biochem. Physiol. , vol.37 , pp. 911-917
    • Bligh, E.G.1    Dyer, W.J.2
  • 23
    • 4344593367 scopus 로고    scopus 로고
    • Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages
    • Boven L.A., van M.M., Boot R.G., Mehta A., Boon L., Aerts J.M., Laman J.D. Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am. J. Clin. Pathol. 2004, 122:359-369.
    • (2004) Am. J. Clin. Pathol. , vol.122 , pp. 359-369
    • Boven, L.A.1    van, M.M.2    Boot, R.G.3    Mehta, A.4    Boon, L.5    Aerts, J.M.6    Laman, J.D.7
  • 24
    • 84858712304 scopus 로고    scopus 로고
    • Urinary globotriaosylsphingosine-related biomarkers for Fabry disease targeted by metabolomics
    • Mar 20
    • Auray-Blais C., Boutin M., Gagnon R., Dupont F.O., Lavoie P., Clarke J.T. Urinary globotriaosylsphingosine-related biomarkers for Fabry disease targeted by metabolomics. Anal. Chem. Mar 20 2012, 84(6):2745-2753.
    • (2012) Anal. Chem. , vol.84 , Issue.6 , pp. 2745-2753
    • Auray-Blais, C.1    Boutin, M.2    Gagnon, R.3    Dupont, F.O.4    Lavoie, P.5    Clarke, J.T.6
  • 25
    • 84873381566 scopus 로고    scopus 로고
    • Multiplex analysis of novel urinary lyso-Gb3-related biomarkers for Fabry disease by tandem mass spectrometry
    • Feb 5
    • Lavoie P., Boutin M., Auray-Blais C. Multiplex analysis of novel urinary lyso-Gb3-related biomarkers for Fabry disease by tandem mass spectrometry. Anal. Chem. Feb 5 2013, 85(3):1743-1752.
    • (2013) Anal. Chem. , vol.85 , Issue.3 , pp. 1743-1752
    • Lavoie, P.1    Boutin, M.2    Auray-Blais, C.3
  • 26
    • 84877987576 scopus 로고    scopus 로고
    • A metabolomic study reveals novel plasma lyso-Gb3 analogs as Fabry disease biomarkers
    • Dupont F.O., Gagnon R., Boutin M., Auray-Blais C. A metabolomic study reveals novel plasma lyso-Gb3 analogs as Fabry disease biomarkers. Curr. Med. Chem. 2013, 20(2):280-288.
    • (2013) Curr. Med. Chem. , vol.20 , Issue.2 , pp. 280-288
    • Dupont, F.O.1    Gagnon, R.2    Boutin, M.3    Auray-Blais, C.4
  • 28
    • 0021813371 scopus 로고
    • Glycosphingolipid studies of visceral tissues and brain from type 1 Gaucher disease variants
    • Nilsson O., Grabowski G.A., Ludman M.D., Desnick R.J., Svennerholm L. Glycosphingolipid studies of visceral tissues and brain from type 1 Gaucher disease variants. Clin. Genet. 1985, 27:443-450.
    • (1985) Clin. Genet. , vol.27 , pp. 443-450
    • Nilsson, O.1    Grabowski, G.A.2    Ludman, M.D.3    Desnick, R.J.4    Svennerholm, L.5
  • 29
    • 0036387220 scopus 로고    scopus 로고
    • Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype
    • Orvisky E., Park J.K., LaMarca M.E., Ginns E.I., Martin B.M., Tayebi N., Sidransky E. Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype. Mol. Genet. Metab. 2002, 76:262-270.
    • (2002) Mol. Genet. Metab. , vol.76 , pp. 262-270
    • Orvisky, E.1    Park, J.K.2    LaMarca, M.E.3    Ginns, E.I.4    Martin, B.M.5    Tayebi, N.6    Sidransky, E.7
  • 31
    • 80051817507 scopus 로고    scopus 로고
    • Sex differences of urinary and kidney globotriaosylceramide and lyso-globotriaosylceramide in Fabry mice
    • Durant B., Forni S., Sweetman L., Brignol N., Meng X.L., Benjamin E.R., et al. Sex differences of urinary and kidney globotriaosylceramide and lyso-globotriaosylceramide in Fabry mice. J. Lipid Res. 2011, 52:1742-1746.
    • (2011) J. Lipid Res. , vol.52 , pp. 1742-1746
    • Durant, B.1    Forni, S.2    Sweetman, L.3    Brignol, N.4    Meng, X.L.5    Benjamin, E.R.6
  • 32
    • 84925884053 scopus 로고    scopus 로고
    • The chemistry and biology of 6-hydroxyceramide, the youngest member of the human sphingolipid family
    • Kováčik A., Roh J., Vávrová K. The chemistry and biology of 6-hydroxyceramide, the youngest member of the human sphingolipid family. Chembiochem 2014, 15(11):1555-1562.
    • (2014) Chembiochem , vol.15 , Issue.11 , pp. 1555-1562
    • Kováčik, A.1    Roh, J.2    Vávrová, K.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.